Literature DB >> 23730316

Supra-additive expression of interleukin-6, interleukin-8 and basic fibroblast growth factor in vascular smooth muscle cells following coinfection with Chlamydia pneumoniae and cytomegalovirus as a novel link between infection and atherosclerosis.

Dirk Prochnau1, Eberhard Straube, Hans-Reiner Figulla, Jürgen Rödel.   

Abstract

BACKGROUND: Chlamydia pneumoniae and human cytomegalovirus (HCMV) may be involved in the pathogenesis of atherosclerosis. Prospective studies indicate an increased risk for cardiovascular events in patients with evidence of multiple infections.
OBJECTIVE: To determine whether there is a synergistic effect of coinfection with C pneumoniae and HCMV on expression of selected growth factors and cytokines.
METHODS: The production of interleukin (IL)-6, IL-8, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and 'regulated on activation normal T-cell expressed and secreted' (RANTES) was measured in coinfected aortic smooth muscle cells (AoSMC).
RESULTS: Using reverse transcription polymerase chain reaction and immunoassays, it was demonstrated that the expression of IL-6, IL-8, RANTES and bFGF was stimulated in a dose- and time-dependent fashion in C pneumoniae and also in HCMV-infected cultures. In contrast, the expression of PDGF-AA was only stimulated following HCMV infection. Coinfection with C pneumoniae and HCMV resulted in a supra-additive stimulation of IL-6 (30% increased expression, P≤0.05) at 48 h, IL-8 (137% increased expression, P≤0.001) at 24 h and bFGF (209% increased expression, P≤0.01) at 48 h following infection.
CONCLUSIONS: The findings of the present study show that C pneumoniae and HCMV are able to act in synergy in coinfected AoSMC. The supra-additive induction of AoSMC growth factors and cytokines indicates a novel molecular link between infection and vascular disease development.

Entities:  

Keywords:  Atherosclerosis; Chlamydia pneumoniae; Coinfection; Cytomegalovirus; Smooth muscle cells

Year:  2012        PMID: 23730316      PMCID: PMC3403668          DOI: 10.1155/2012/987476

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  38 in total

1.  Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis.

Authors:  H S Markus; M Sitzer; D Carrington; M A Mendall; H Steinmetz
Journal:  Circulation       Date:  1999-08-24       Impact factor: 29.690

Review 2.  Chlamydia pneumoniae and coronary artery disease: the antibiotic trials.

Authors:  John P Higgins
Journal:  Mayo Clin Proc       Date:  2003-03       Impact factor: 7.616

3.  Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION, and the HF-ACTION trial.

Authors:  John G F Cleland; P Huan Loh; Nick Freemantle; Andrew L Clark; Alison P Coletta
Journal:  Eur J Heart Fail       Date:  2004-10       Impact factor: 15.534

Review 4.  Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signalling cascades.

Authors:  Jan Marco Kern; Viola Maass; Matthias Maass
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

5.  PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms.

Authors:  Li Li; Donald K Blumenthal; Christi M Terry; Yuxia He; Mary L Carlson; Alfred K Cheung
Journal:  J Cell Biochem       Date:  2011-01       Impact factor: 4.429

6.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Authors:  Christopher M O'Connor; Michael W Dunne; Marc A Pfeffer; Joseph B Muhlestein; Louis Yao; Sandeep Gupta; Rebecca J Benner; Marian R Fisher; Thomas D Cook
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

7.  Active cytomegalovirus infection in aortic smooth muscle cells from patients with abdominal aortic aneurysm.

Authors:  Sara Gredmark-Russ; Mensur Dzabic; Afsar Rahbar; Anders Wanhainen; Martin Björck; Erik Larsson; Jean-Baptiste Michel; Cecilia Söderberg-Nauclér
Journal:  J Mol Med (Berl)       Date:  2008-12-16       Impact factor: 4.599

8.  Chlamydia pneumoniae infection of aortic smooth muscle cells reduces platelet-derived growth factor receptor-beta expression.

Authors:  Jürgen Rödel; Marc Lehmann; Heinz Vogelsang; Eberhard Straube
Journal:  FEMS Immunol Med Microbiol       Date:  2007-08-29

Review 9.  Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing.

Authors:  D N Streblow; J Dumortier; A V Moses; S L Orloff; J A Nelson
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

10.  Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-κB pathway.

Authors:  Fragiska Sigala; Paraskevi Savvari; Michalis Liontos; Panagiotis Sigalas; Ioannis S Pateras; Alexandros Papalampros; Efthimia K Basdra; Evangelos Kolettas; Athanasios G Papavassiliou; Vassilis G Gorgoulis
Journal:  J Cell Mol Med       Date:  2010-09       Impact factor: 5.310

View more
  5 in total

Review 1.  Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases.

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int Immunopharmacol       Date:  2022-06-28       Impact factor: 5.714

Review 2.  Infectious burden and atherosclerosis: A clinical issue.

Authors:  Rosa Sessa; Marisa Di Pietro; Simone Filardo; Ombretta Turriziani
Journal:  World J Clin Cases       Date:  2014-07-16       Impact factor: 1.337

Review 3.  An Unsettled Debate About the Potential Role of Infection in Pathogenesis of Atherosclerosis.

Authors:  Udip Dahal; Dikshya Sharma; Kumud Dahal
Journal:  J Clin Med Res       Date:  2017-05-22

Review 4.  Human cytomegalovirus infection and coronary heart disease: a systematic review.

Authors:  Yu Du; Guangxue Zhang; Zhijun Liu
Journal:  Virol J       Date:  2018-02-06       Impact factor: 4.099

Review 5.  Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism.

Authors:  Lingxiang Xie; Yang Xiao; Shi Tai; Huijie Yang; Shenghua Zhou; Zhiguang Zhou
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.